Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy.

Ravi R, Noonan KA, Pham V, Bedi R, Zhavoronkov A, Ozerov IV, Makarev E, V Artemov A, Wysocki PT, Mehra R, Nimmagadda S, Marchionni L, Sidransky D, Borrello IM, Izumchenko E, Bedi A. · 2018

Read Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy. by Ravi R, Noonan KA, Pham V, Bedi R, Zhavoronkov A, Ozerov IV, Makarev E, V Artemov A, Wysocki PT, Mehra R, Nimmagadda S, Marchionni L, Sidransky D, Borrello IM, Izumchenko E, Bedi A. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5821872.txt.

Introduction

Ravi and co-authors build two-in-one traps to boost cancer immunotherapy. Checkpoint drugs free immune cells to attack tumors. Most cancers still fail to respond. Tumors often secrete TGF-beta, which damps immune attack and grows regulator cells.

Their Y-traps fuse a checkpoint antibody to a TGF-beta catcher. One version targets CTLA-4, and one targets PD-L1. Each blocks its checkpoint while mopping up TGF-beta nearby. In tests, both beat the standard antibodies they mimic. Tumors held fewer regulator T cells and grew slower. Readers get a clever design aimed at cancers that shrug off current immune drugs.

Catalog record

CREATORRavi R, Noonan KA, Pham V, Bedi R, Zhavoronkov A, Ozerov IV, Makarev E, V Artemov A, Wysocki PT, Mehra R, Nimmagadda S, Marchionni L, Sidransky D, Borrello IM, Izumchenko E, Bedi A.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE77 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5821872

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy By Rajani Ravi, Kimberly A Noonan, Vui Pham, Rishi Bedi, Alex Zhavoronkov, Ivan V Ozerov, Eugene Makarev, Artem V Artemov, Piotr T Wysocki, Ranee Mehra, Sridhar Nimmagadda, Luigi Marchionni Published in: Nature Communications DOI: 10.1038/s41467-017-02696-6 ABSTRACT Abstract A majority of cancers fail to respond to immunotherapy with antibodies targeting immune checkpoints, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) or programmed death-1 (PD-1)/PD-1 ligand (PD-L1). Cancers frequently express transforming growth factor-β (TGFβ), which drives immune dysfunction in the tumor microenvironment by inducing regulatory T cells (Tregs) and inhibiting CD8+ and TH1 cells. To address this therapeutic challenge, we invent bifunctional antibody–ligand traps (Y-traps) comprising an antibody targeting CTLA-4 or PD-L1 fused to a TGFβ receptor II ectodomain sequence that simultaneously disables autocrine/paracrine TGFβ in the target cell microenvironment (a-CTLA4-TGFβRIIecd and a-PDL1-TGFβRIIecd). a-CTLA4-TGFβRIIecd is more effective in reducing tumor-infiltrating Tregs and inhibiting tumor progression compared with CTLA-4 antibody (Ipilimumab). Likewise, a-PDL1-TGFβRIIecd exhibits superior antitumor efficacy compared with PD-L1 antibodies (Atezolizumab or Avelumab). Our data demonstrate that Y-traps counteract TGFβ-mediated differentiation of Tregs and immune tolerance, thereby providing a potentially more effective immunotherapeutic strategy against cancers that are resistant to current immune checkpoint inhibitors. INTRODUCTION Genetic mutations accruing from the inherent genomic instability of tumor cells present neo-antigens that are recognized by the immune system. Cross-presentation of tumor antigens at the immune synapse between antigen-presenting dendritic cells and T lymphocytes can potentially activate an adaptive antitumor immune response that is mediated by CD4+ T-helper cells (TH1) and CD8+ cytotoxic effector cells, and sustained by tumor-reactive central memory T cells1. However, tumors continuously evolve to counteract and ultimately defeat such immune surveillance by co-opting and amplifying mechanisms of immune tolerance to evade elimination by the immune system1–3. This prerequisite for tumor progression is enabled by the ability of cancers to produce immunomodulatory factors that create a tolerogenic immune cell microenvironment3. Transforming growth factor-β (TGFβ) is a multifunctional cytokine that is overexpressed in a majority of cancers4. The high-affinity binding of TGFβ to TGFβ receptor II (TGFβRII) recruits TGFβ receptor I into a heterotetrameric complex that initiates SMAD-mediated transcriptional activation or repression of several genes that control cell growth, differentiation, and migration5. Besides promoting epithelial-to-mesenchymal transition, invasion, and metastases of tumor cells, TGFβ has a critical role in regulating the adaptive immune system6–9. TGFβ suppresses the expression of interferon-γ (IFN-γ), restricts the differentiation of TH1 cells, attenuates the activation and cytotoxic function of CD8+ effector cells, and inhibits the development of central memory T cells8–11. Most significantly, TGFβ induces the differentiation of regulatory T cells (Tregs), a sub-population of immunosuppressive CD4+ T cells that express the interleukin-2 α-chain (CD25) and the forkhead box P3 (FOXP3) transcription factor12–18. TGFβ induces the expression of FOXP3, the signature transcription factor that determines and maintains the functional program of the Treg lineage19–23. FOXP3, in turn, induces the expression of cytotoxic T lymphocyte antigen-4 (CTLA-4), an immune-inhibitory receptor that restrains co-stimulation of T cells, and Galectin-9 (GAL-9), a ligand that engages the T-cell immunoglobulin domain and mucin domain-3 (TIM-3) immune-inhibitory receptor, and triggers exhaustion or apoptosis of effector T cells24–28. GAL-9 further interacts with TGFβ receptors to drive FOXP3 expression in a positive-feed forward autocrine loop involving SMAD3 activation to induce and maintain Tregs29. This ability of TGFβ to skew the differentiation of CD4+ T cells away from a TH1 phenotype toward a Treg lineage has significant clinical implications, as the functional orientation of tumor-infiltrating immune cells has a major impact on the outcome of patients with cancer30. Whereas TH1 cells, cytotoxic CD8+ T cells and central memory T cells are uniformly and strongly associated with a longer disease-free survival, infiltration of tumors with Tregs has been correlated with a poor prognosis in patients with several types of cancer30–35. Current clinical efforts to counteract tumor-induced immune tolerance are focused on monoclonal antibodies, which counteract T-cell inhibitory receptors that function as immune checkpoints, such as CTLA-4 or programmed death-1 (PD-1)/PD-1 ligand (PD-L1)36–41. The CTLA-4 blocking antibody (Ipilimumab), two PD-1 antagonists (Pembrolizumab and Nivolumab), and three PD-L1 inhibitors (Atezolizumab, Avelumab, and Durvalumab) are currently approved in specific clinical indications for immunotherapy of cancers, such as melanoma, non-small cell lung cancer, head and neck cancer, or bladder cancer. Although a subset of patients with advanced cancers experience durable remissions and prolonged survival in response to CTLA-4 or PD-1/PD-L1 checkpoint inhibitors, the majority of patients do not respond to such therapy42,43. A potential limitation of T-cell co-stimulation by current immune checkpoint inhibitors is a tumor milieu enriched with TGFβ, which strongly correlated with FOXP3 expression in our analysis of The Cancer Genome Atlas (TCGA) data set of diverse human cancers, including melanoma and breast cancer. We hypothesized that autocrine and paracrine TGFβ signaling in the localized microenvironment of tumor-infiltrating T cells could skew them toward Tregs and attenuate the activation of TH1 and CD8+ immune effector cells, thereby limiting the therapeutic efficacy of CTLA-4 or PD-1/PD-L1 antagonists44,45. As Tregs express and employ TGFβ and Gal-9 to maintain their own phenotype and function, enhancing the efficacy of immune checkpoint inhibitors requires a strategy to specifically break this hyperactive autocrine loop in tumor-infiltrating Tregs. To test this hypothesis and address this therapeutic challenge, we invented bifunctional antibody-ligand traps (Y-traps) comprising an antibody targeting either CTLA-4 or PD-L1, which is fused at the C terminus of the heavy chain (HC) to a TGFβRII ectodomain sequence to sequester and disable autocrine/paracrine TGFβ in the target cell microenvironment (a-CTLA4-TGFβRIIecd and a-PDL1-TGFβRIIecd)46,47–49. We find that a-CTLA4-TGFβRIIecd is significantly more effective in reducing and counteracting tumor-infiltrating Tregs, activating antitumor immunity, and inhibiting tumor progression compared with the CTLA-4 antibody, Ipilimumab. Likewise, a-PDL1-TGFβRIIecd exhibits superior antitumor efficacy compared with PD-L1 antibodies (Atezolizumab or Avelumab). Our data demonstrate that Y-traps simultaneously disable immune checkpoints and counteract TGFβ-mediated differentiation of Tregs and immune tolerance, thereby providing a more effective immunotherapeutic strategy against cancers that fail to respond to current immune checkpoint inhibitors. RESULTS TGFβ signaling correlates with FOXP3 expression in cancers We used iPANDA, a bioinformatics software suite for qualitative analysis of intracellular signaling pathway activation based on transcriptomic data50,51, to assess the level of TGFβ signaling in TCGA data sets of different types of cancer and investigate whether the TGFβ pathway activation in tumors is correlated with the level of expression of FOXP3, the signature transcription factor of the Treg lineage. Analysis of transcriptomic data from a skin cutaneous melanoma (SKCM) data set (n = 472), using skin biopsy of healthy women (n = 122) as a reference, showed that upregulation in TGFβ signaling strongly correlated with increased messenger RNA expression levels of TGFB1 and FOXP3 (Fig. 1a, b). The strong correlation between TGFβ pathway activation and FOXP3 expression was also noted in a TCGA breast cancer data set (n = 776), using normal breast tissue as a reference (Fig. 1c, d). Among breast cancers, TGFβ pathway activation and corresponding elevation of FOXP3 was especially striking in triple-negative breast cancer (TNBC) (Fig. 1c), an aggressive subtype that lacks expression of hormone receptors (estrogen receptor (ER)/progesterone receptor (PR)) and HER2/neu, and has a higher risk of metastases and death within 5 years of diagnosis. Although TGFβ and PD-L1 can cooperate

Read the complete text